OncoImmunology

Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. We now create a new, high-profile journal, OncoImmunology, that specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever growing suspicion that - unexpectedly - many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies

 

    Related Conference of OncoImmunology

    January 03-04, 2023

    International Congress on HIV-Aids and STD's

    London, UK
    February 15-16, 2023

    11th World Summit on Immunology and Immunotherapy

    Zurich, Switzerland
    February 20-21, 2023

    Global Summit on SARS-CoV-2 virus

    Madrid, Spain
    February 21-22, 2023

    4th European Congress on Hematology

    Zurich, Switzerland
    May 24-25, 2023

    37th International Conference on Immunology

    Vienna, Austria

    OncoImmunology Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in